The global prevalence of peripheral neuropathy following chemotherapy in cancer patients: a systematic review and meta-analysis
Background Chemotherapy-induced peripheral neuropathy (CIPN) is a major cause of dose reduction, drug modification, or drug discontinuation in cancer patients which negatively impacts the overall well-being of cancer patients and medication procedures. This systematic review and meta-analysis inve...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | en |
| Published: |
Springer Science and Business Media LLC
2026
|
| Subjects: | |
| Online Access: | http://psasir.upm.edu.my/id/eprint/124084/1/124084.pdf http://psasir.upm.edu.my/id/eprint/124084/ https://link.springer.com/article/10.1186/s13023-026-04256-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background Chemotherapy-induced peripheral neuropathy (CIPN) is a major cause of dose reduction, drug
modification, or drug discontinuation in cancer patients which negatively impacts the overall well-being of cancer
patients and medication procedures. This systematic review and meta-analysis investigation aimed to determine the
global prevalence of CIPN in cancer patients.
Methods Various scientific databases (PubMed, Scopus, Web of Science, Embase, ScienceDirect, and Google Scholar)
were systematically searched (by July 2023) for published studies reporting the CIPN prevalence. Meta-analysis
was applied based on the Random Effect model and subgrouping was considered using the CIPN scales. Also, the
heterogeneity was assessed based on the I2 index.
Results Following the assessment of 49 eligible studies (n:33,667 participants), the overall CIPN prevalence was
reported 51.9% (95% CI: 45-58.7). According to the Composite Scales tool, the highest CIPN prevalence was 69.6%
(95%CI: 50–84).
Conclusion The prevalence of CIPN in cancer patients was found at a high level. According to the high number of
cancer survivors, the integration of necessary clinical strategies for screening, prevention, and treatment of CIPN into
consistent clinical guidelines is strictly recommended. Probably these guidelines can reduce the CIPN occurrence andcancer treatment costs.
Clinical trial number Not applicable. |
|---|